Actelion Acquisition: The acquisition gives JNJ five currently-marketed therapies (Opsumit, Tracleer, Uptravi, Veletri
and Ventavis) for the treatment of pulmonary hypertension and two currently-marketed specialty products, Valchlor gel (cutaneous T-cell lymphoma) and Zavesca (Gaucher disease in the U.S./Nieman-Pick disease in Europe).
Actelion is a highly profitable life science firm as a result of our leading franchise in pulmonary arterial hypertension (PAH), where our three marketed products Tracleer, Ventavis and Veletri
continue to bring significant value to patients.
M2 PHARMA-August 27, 2010-Actelion says FDA OKs brand name VELETRI for epoprostenol for injection therapy(C)2010 M2 COMMUNICATIONS
27 August 2010 - Actelion Pharmaceuticals US Inc, part of Swiss Actelion Ltd (VTX: ATLN), said on Wednesday that the US Food and Drug Administration (FDA) has approved the brand name VELETRI for the company's epoprostenol for injection therapy.
VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease.
VELETRI is an improved formulation of epoprostenol that offers greater convenience to patients than other epoprostenol formulations, the company said.
In conjunction with the launch of VELETRI, Actelion opened its fourth PAH patient registry in the US.
Actelion said it will also provide further information on VELETRI at the American Heart Association Scientific Sessions 2010 in Chicago with a poster entitled "Biocomparability of Two Formulations of Epoprostenol, Epoprostenol for Injection (ACT-385781A) And Flolan, Via Pharmacokinetic Assessment of Two Primary Metabolites."
(19) The Italian military scenes in Don Alvaro o la fuerza del sino take place in Veletri
, near the place where in 1744 Austrian Imperial forces were defeated by Spanish and Neapolitan troops led by Carlos de Borbon, King of Naples.
-- Veletri(TM) (tezosentan): With partner Actelion Ltd., announced the second pivotal Phase III clinical trial of Veletri
-- an intravenous dual endothelin receptor antagonist -- did not meet its primary objective of significantly improving symptoms (dyspnea, or shortness of breath) associated with acute heart failure.
), the first dual en dothelin receptor antagonist, offered clinically significant hemodynamic benefits in a randomized double-blind multicenter trial involving 292 .patients hospitalized for acute decompensated heart failure.